688289 圣湘生物
已收盘 04-15 15:00:01
资讯
新帖
简况
圣湘生物(688289)披露拟注册发行不超过10亿元中期票据,4月15日股价下跌0.16%
证券之星 · 04-15 22:19
圣湘生物(688289)披露拟注册发行不超过10亿元中期票据,4月15日股价下跌0.16%
每周股票复盘:圣湘生物(688289)拟注册发行中期票据
证券之星 · 04-12
每周股票复盘:圣湘生物(688289)拟注册发行中期票据
圣湘生物(688289.SH)拟注册发行不超10亿元中期票据
智通财经 · 04-07
圣湘生物(688289.SH)拟注册发行不超10亿元中期票据
每周股票复盘:圣湘生物(688289)临时股东会通过对外投资议案
证券之星 · 04-05
每周股票复盘:圣湘生物(688289)临时股东会通过对外投资议案
圣湘生物(688289)披露关于与关联方共同投资华斯无微生物科技(深圳)有限公司的议案,4月3日股价下跌2.63%
证券之星 · 04-03
圣湘生物(688289)披露关于与关联方共同投资华斯无微生物科技(深圳)有限公司的议案,4月3日股价下跌2.63%
圣湘生物最新公告:拟与关联方共同投资设立合资公司并收购华斯无微100%股权
中金财经 · 03-15
圣湘生物最新公告:拟与关联方共同投资设立合资公司并收购华斯无微100%股权
圣湘生物(688289)披露与关联方共同投资北京哲源科技公告,3月13日股价上涨0.38%
证券之星 · 03-13
圣湘生物(688289)披露与关联方共同投资北京哲源科技公告,3月13日股价上涨0.38%
圣湘生物新注册《两方径向基核函数计算的隐私保护软件V1.0》等5个项目的软件著作权
证券之星 · 03-07
圣湘生物新注册《两方径向基核函数计算的隐私保护软件V1.0》等5个项目的软件著作权
圣湘生物(688289)披露2025年度业绩快报公告,3月2日股价下跌3.65%
证券之星 · 03-02
圣湘生物(688289)披露2025年度业绩快报公告,3月2日股价下跌3.65%
每周股票复盘:圣湘生物(688289)2025年净利降28.10%
证券之星 · 03-01
每周股票复盘:圣湘生物(688289)2025年净利降28.10%
圣湘生物最新公告:控股子公司产品新增适应症获得临床试验批准
证券之星 · 02-26
圣湘生物最新公告:控股子公司产品新增适应症获得临床试验批准
1月28日圣湘生物跌6.56%,银河医药混合A基金重仓该股
中金财经 · 01-28
1月28日圣湘生物跌6.56%,银河医药混合A基金重仓该股
1月26日圣湘生物涨8.97%,银河医药混合A基金重仓该股
证券之星 · 01-26
1月26日圣湘生物涨8.97%,银河医药混合A基金重仓该股
圣湘生物(688289)披露2023年第二期限制性股票激励计划首次授予部分第一个归属期归属结果公告,12月19日股价上涨0.26%
证券之星 · 2025-12-19
圣湘生物(688289)披露2023年第二期限制性股票激励计划首次授予部分第一个归属期归属结果公告,12月19日股价上涨0.26%
圣湘生物(688289)披露相关产品取得医疗器械注册证,12月16日股价下跌1.96%
证券之星 · 2025-12-16
圣湘生物(688289)披露相关产品取得医疗器械注册证,12月16日股价下跌1.96%
圣湘生物(688289.SH):四款产品取得医疗器械注册证
智通财经 · 2025-12-16
圣湘生物(688289.SH):四款产品取得医疗器械注册证
圣湘生物(688289)披露相关产品获得欧盟CE认证,12月12日股价下跌0.37%
证券之星 · 2025-12-12
圣湘生物(688289)披露相关产品获得欧盟CE认证,12月12日股价下跌0.37%
圣湘生物(688289.SH):全自动核酸处理系统(S-S13E-P/S-S13E-P1)获得欧盟CE认证
智通财经 · 2025-12-11
圣湘生物(688289.SH):全自动核酸处理系统(S-S13E-P/S-S13E-P1)获得欧盟CE认证
圣湘生物某股东股份拟被司法冻结 上市即巅峰超募13亿
中金财经 · 2025-12-08
圣湘生物某股东股份拟被司法冻结 上市即巅峰超募13亿
圣湘生物(688289)披露2023年第二期限制性股票激励计划首次授予部分第一个归属期符合归属条件,11月28日股价下跌0.2%
证券之星 · 2025-11-28
圣湘生物(688289)披露2023年第二期限制性股票激励计划首次授予部分第一个归属期符合归属条件,11月28日股价下跌0.2%
加载更多
公司概况
公司名称:
圣湘生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-08-28
主营业务:
圣湘生物科技股份有限公司的主营业务是提供诊断试剂、仪器、第三方医学检验服务为一体的体外诊断整体解决方案。公司的主要产品是诊断试剂、诊断仪器、检测服务。公司连续两年荣登全球医疗器械企业TOP100榜单,入选“国家企业技术中心”“湖南省制造业创新中心”,在iDASH国际隐私计算竞赛中斩获全球第一名,长沙高新区仓储物流中心获批国家级行业认证“五星级仓库”。董事长戴立忠先生当选中国思南峰会2024-2025轮值主席、第三届中国慈善联合会副会长、第四届湖南省慈善总会副会长等职务,并先后作为第十三届、十四届全国人大代表在生命健康领域建言献策,“圣湘声音”与国家战略高度同频共振。
发行价格:
50.48
{"stockData":{"symbol":"688289","market":"SH","secType":"STK","nameCN":"圣湘生物","latestPrice":18.26,"timestamp":1776236401000,"preClose":18.29,"halted":0,"volume":2602107,"delay":0,"changeRate":-0.0016,"floatShares":579000000,"shares":579000000,"eps":0.4686,"marketStatus":"已收盘","change":-0.03,"latestTime":"04-15 15:00:01","open":18.29,"high":18.39,"low":18.24,"amount":47662900,"amplitude":0.0082,"askPrice":18.27,"askSize":50,"bidPrice":18.26,"bidSize":112,"shortable":0,"etf":0,"ttmEps":0.4686,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":18.29,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":20.12,"lowLimit":16.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":579388006,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":38.967136,"roe":"2.63%","epsLYR":0.47,"committee":-0.022269,"marketValue":10580000000,"turnoverRate":0.0045,"status":1,"afterMarket":{"amount":0,"volume":0,"close":18.26,"buyVolume":0,"sellVolume":0,"time":1776238437558,"indexStatus":"已收盘 04-15 15:30:00","preClose":18.29},"floatMarketCap":10580000000},"requestUrl":"/m/hq/s/688289","defaultTab":"news","newsList":[{"id":"2627023872","title":"圣湘生物(688289)披露拟注册发行不超过10亿元中期票据,4月15日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627023872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627023872?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:19","pubTimestamp":1776262755,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘,圣湘生物报收于18.26元,较前一交易日下跌0.16%,最新总市值为105.8亿元。该股当日开盘18.29元,最高18.39元,最低18.24元,成交额达4766.29万元,换手率为0.45%。近日,圣湘生物科技股份有限公司披露《2026年第二次临时股东会会议资料》。本次发行授权董事会全权办理相关事宜,授权有效期自股东会审议通过之日起,在注册和存续有效期内持续有效。该事项已由公司董事会审议通过,尚需交易商协会注册批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500043117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626122613","title":"每周股票复盘:圣湘生物(688289)拟注册发行中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2626122613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626122613?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:54","pubTimestamp":1775930053,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,圣湘生物报收于18.31元,较上周的17.76元上涨3.1%。本周,圣湘生物4月8日盘中最高价报18.53元。圣湘生物当前最新总市值106.09亿元,在医疗器械板块市值排名33/129,在两市A股市值排名1879/5196。本周关注点公司公告汇总:圣湘生物拟注册和发行中期票据,并召开临时股东会审议该议案。会议审议《关于拟注册和发行中期票据的议案》,对中小投资者单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625895847","title":"圣湘生物(688289.SH)拟注册发行不超10亿元中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2625895847","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625895847?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:38","pubTimestamp":1775565510,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣湘生物(688289.SH)发布公告,公司拟向中国银行间市场交易商协会申请注册并发行不超过10亿元(含10亿元)的中期票据,并根据市场情况以及自身资金需求状况在注册额度内择机一次性或分期发行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625164136","title":"每周股票复盘:圣湘生物(688289)临时股东会通过对外投资议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2625164136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625164136?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:17","pubTimestamp":1775326629,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,圣湘生物报收于17.76元,较上周的18.28元下跌2.84%。本周关注点公司公告汇总:圣湘生物2026年第一次临时股东会审议通过与关联方共同投资华斯无微生物科技(深圳)有限公司的议案。圣湘生物科技股份有限公司于2026年3月31日召开2026年第一次临时股东会,会议由董事彭铸主持,采用现场与网络投票相结合方式召开。出席会议的股东共307人,代表有表决权股份总数56,971,929股,占公司表决权总数的9.9105%。关联股东未出席本次会议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688289"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591736","title":"圣湘生物(688289)披露关于与关联方共同投资华斯无微生物科技(深圳)有限公司的议案,4月3日股价下跌2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624591736?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:40","pubTimestamp":1775209229,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,圣湘生物报收于17.76元,较前一交易日下跌2.63%,最新总市值为102.9亿元。该股当日开盘18.19元,最高18.22元,最低17.75元,成交额达7054.79万元,换手率为0.68%。公告显示,公司于2026年3月31日召开2026年第一次临时股东会,审议通过《关于与关联方共同投资华斯无微生物科技(深圳)有限公司的议案》。关联股东未出席本次会议。湖南启元律师事务所对本次会议进行了见证并出具法律意见书,认为会议决议合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HBImain","BK0239","159837","688289"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619059531","title":"圣湘生物最新公告:拟与关联方共同投资设立合资公司并收购华斯无微100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2619059531","media":"中金财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619059531?lang=zh_cn&edition=full","pubTime":"2026-03-15 18:24","pubTimestamp":1773570244,"startTime":"0","endTime":"0","summary":"圣湘生物(688289.SH)公告称,公司拟与关联方湖南金芙蓉圣湘生物股权投资基金合伙企业共同投资设立湖南圣维华斯生物技术有限公司,并将其作为后续收购华斯无微生物科技(深圳)有限公司100%股权的投资主体。其中,公司以自有资金出资6543.80万元,交易完成后,合资公司及华斯无微将纳入公司合并报表范围。为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260315/32069420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688289"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619198555","title":"圣湘生物(688289)披露与关联方共同投资北京哲源科技公告,3月13日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619198555?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:23","pubTimestamp":1773393797,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,圣湘生物报收于18.28元,较前一交易日上涨0.38%,最新总市值为105.91亿元。圣湘生物科技股份有限公司于近日披露《关于与关联方共同投资北京哲源科技有限责任公司的公告》。公告显示,公司拟与关联方湖南金芙蓉圣湘生物股权投资基金合伙企业共同投资北京哲源科技有限责任公司;圣湘生物以自有资金投资4,000.00万元,基金投资5,000.00万元,通过受让股权及增资后,公司将持有哲源科技4.02%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688289"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617632340","title":"圣湘生物新注册《两方径向基核函数计算的隐私保护软件V1.0》等5个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2617632340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617632340?lang=zh_cn&edition=full","pubTime":"2026-03-07 01:55","pubTimestamp":1772819716,"startTime":"0","endTime":"0","summary":"证券之星消息,近日圣湘生物新注册了5个项目的软件著作权,包括《两方径向基核函数计算的隐私保护软件V1.0》、《基于CKKS同态加密的LightGBM决策树推理软件V1.0》、《LightGBM 树结构聚类与填充软件V1.0》、《融合同态加密与多方安全计算的核支持向量机训练软件V1.0》、《基于同态加密的隐私保护主成分分析软件V1.0》等。今年以来圣湘生物新注册软件著作权5个,较去年同期增加了400%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030700000217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688289"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616138744","title":"圣湘生物(688289)披露2025年度业绩快报公告,3月2日股价下跌3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616138744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616138744?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:36","pubTimestamp":1772444188,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,圣湘生物报收于18.5元,较前一交易日下跌3.65%,最新总市值为107.19亿元。该股当日开盘18.99元,最高19.13元,最低18.5元,成交额达1.7亿元,换手率为1.57%。圣湘生物科技股份有限公司于近日披露《2025年度业绩快报公告》。公告显示,公司2025年营业总收入为16.48亿元,同比增长13.04%;营业利润为2.02亿元,同比下降27.13%;归属于母公司所有者的净利润为1.98亿元,同比下降28.10%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200025979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843955","title":"每周股票复盘:圣湘生物(688289)2025年净利降28.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843955","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843955?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:02","pubTimestamp":1772301738,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,圣湘生物报收于19.2元,较上周的19.31元下跌0.57%。本周,圣湘生物2月25日盘中最高价报19.68元。圣湘生物当前最新总市值111.24亿元,在医疗器械板块市值排名33/129,在两市A股市值排名1920/5189。圣湘生物科技股份有限公司2025年度业绩快报显示,营业总收入16.48亿元,同比增长13.04%;营业利润2.02亿元,同比下降27.13%;归属于母公司所有者的净利润1.98亿元,同比下降28.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688289"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614012057","title":"圣湘生物最新公告:控股子公司产品新增适应症获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614012057","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614012057?lang=zh_cn&edition=full","pubTime":"2026-02-26 18:39","pubTimestamp":1772102381,"startTime":"0","endTime":"0","summary":"圣湘生物(688289.SH)公告称,公司控股子公司中山圣湘海济生物医药有限公司的产品人生长激素注射液(商品名称:海之元)拟新增用于特发性矮身材(ISS)的适应症补充申请已获得国家药监局的临床试验批准。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600030511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606796031","title":"1月28日圣湘生物跌6.56%,银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606796031","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606796031?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:49","pubTimestamp":1769590149,"startTime":"0","endTime":"0","summary":"证券之星消息,1月28日圣湘生物跌6.56%,收盘报20.67元,换手率4.87%,成交量28.21万手,成交额5.91亿元。重仓圣湘生物的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元,最新净值0.6237,较上一交易日下跌0.94%,近一年上涨29.67%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/28/20260128602037.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/28/20260128602037.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260128/31979473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09939","159938","688289","BK1515","BK0239","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606895297","title":"1月26日圣湘生物涨8.97%,银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606895297","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606895297?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:41","pubTimestamp":1769413317,"startTime":"0","endTime":"0","summary":"证券之星消息,1月26日圣湘生物涨8.97%创60日新高,收盘报21.98元,换手率6.54%,成交量37.9万手,成交额8.26亿元。重仓圣湘生物的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元,最新净值0.6321,较上一交易日上涨1.84%,近一年上涨31.41%。该公募基金现任基金经理为方伟。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600014977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688289","09939","BK1515","159938","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592916070","title":"圣湘生物(688289)披露2023年第二期限制性股票激励计划首次授予部分第一个归属期归属结果公告,12月19日股价上涨0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916070","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592916070?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:18","pubTimestamp":1766153925,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,圣湘生物报收于19.18元,较前一交易日上涨0.26%,最新总市值为111.13亿元。近日,圣湘生物科技股份有限公司发布关于2023年第二期限制性股票激励计划首次授予部分第一个归属期归属结果的公告。公告显示,公司已完成该次激励计划首次授予部分第一个归属期的股份登记,本次归属股票数量为684,199股,来源为公司从二级市场回购的A股普通股股票。本次归属不导致公司总股本、控股股东及实际控制人持股比例发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591945980","title":"圣湘生物(688289)披露相关产品取得医疗器械注册证,12月16日股价下跌1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591945980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591945980?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:12","pubTimestamp":1765894370,"startTime":"0","endTime":"0","summary":"截至2025年12月16日收盘,圣湘生物报收于18.51元,较前一交易日下跌1.96%,最新总市值为107.24亿元。公司近日发布公告称,圣湘生物科技股份有限公司的四款产品近日获得国家药品监督管理局颁发的《医疗器械注册证》。上述产品均为境内第三类体外诊断试剂,有效期至2030年12月11日。此次获批丰富了公司呼吸道感染快速检测体系,提升了EB病毒检测能力,并扩展了药物基因组学应用,有助于临床精准用药和疾病管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600040620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1222","09996","BK1574","688289","09997","BK0239","BK1583","BK1100","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591798639","title":"圣湘生物(688289.SH):四款产品取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591798639","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591798639?lang=zh_cn&edition=full","pubTime":"2025-12-16 19:12","pubTimestamp":1765883539,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣湘生物(688289.SH)发布公告,公司的四款产品于近日收到由国家药品监督管理局颁发的《医疗器械注册证》,产品名称分别为:大肠埃希菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌核酸检测试剂盒(荧光PCR法);肺炎链球菌、流感嗜血杆菌、卡他莫拉菌核酸检测试剂盒(荧光PCR法);人CYP3A5基因多态性核酸检测试剂盒(PCR-荧光探针法);EB病毒核酸检测试剂盒(荧光PCR法)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688289","09996","BK1574","BK1100","09997","BK1583","BK1222","159883","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590577880","title":"圣湘生物(688289)披露相关产品获得欧盟CE认证,12月12日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577880?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:52","pubTimestamp":1765533166,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘,圣湘生物报收于18.76元,较前一交易日下跌0.37%,最新总市值为108.69亿元。该股当日开盘18.89元,最高18.94元,最低18.7元,成交额达6861.85万元,换手率为0.63%。圣湘生物科技股份有限公司近日发布公告称,公司全自动核酸处理系统近日获得欧盟CE IVDR认证,证书编号CMB 1012-2025,有效期长期,适用范围为欧盟国家及认可该认证的国家。此次认证标志着公司分子诊断技术国际化进程的重要进展。产品销售及未来业绩存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200028715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","FSXEmain","688289","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590488592","title":"圣湘生物(688289.SH):全自动核酸处理系统(S-S13E-P/S-S13E-P1)获得欧盟CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2590488592","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590488592?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:36","pubTimestamp":1765449376,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣湘生物 发布公告,公司的产品全自动核酸处理系统于近日获得欧盟CEIVDR认证。该款仪器本次获得欧盟CEIVDR认证,标志着公司在分子诊断技术国际化与标准化进程迈出关键一步。这一里程碑不仅体现了产品的卓越性能与安全标准,更展现了公司引领行业创新、服务全球市场的坚定承诺。未来,公司将持续推动技术革新与方案融合,赋能全球医疗机构与公共卫生体系,助力构建更高效、精准、可靠的健康防控新生态。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CE","FESXmain","688289","FSXEmain","BK0239","BK4588","BK4109","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589970380","title":"圣湘生物某股东股份拟被司法冻结 上市即巅峰超募13亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2589970380","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589970380?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:47","pubTimestamp":1765180028,"startTime":"0","endTime":"0","summary":"中国经济网北京12月8日讯 圣湘生物 于12月5日晚间发布关于持股5%以上股东部分股份拟被司法冻结并强制执行的提示性公告。 圣湘生物于近日收到湖南省株洲市中级人民法院下发的湘02执1204号《协助执行通知书》,获悉公司持股5%以上股东陈文义所持公司的部分股份拟被司法冻结并强制执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251208/31850501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688289","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586107738","title":"圣湘生物(688289)披露2023年第二期限制性股票激励计划首次授予部分第一个归属期符合归属条件,11月28日股价下跌0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586107738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586107738?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:14","pubTimestamp":1764339269,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘,圣湘生物报收于20.22元,较前一交易日下跌0.2%,最新总市值为117.15亿元。该股当日开盘20.26元,最高20.35元,最低20.15元,成交额达5961.95万元,换手率为0.51%。近日,圣湘生物科技股份有限公司发布关于2023年第二期限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告。公告称,本次激励计划首次授予部分第一个归属期的归属条件已成就,拟归属限制性股票数量为684,199股,股票来源为公司从二级市场回购的A股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688289"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776282168135,"stockEarnings":[{"period":"1week","weight":-0.0114},{"period":"1month","weight":-0.0354},{"period":"3month","weight":-0.0942},{"period":"6month","weight":-0.0951},{"period":"1year","weight":-0.0388},{"period":"ytd","weight":-0.0344}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"圣湘生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21641人(较上一季度增加4.17%)","perCapita":"26772股","listingDate":"2020-08-28","address":"湖南省长沙市岳麓区高新技术产业开发区麓松路680号","registeredCapital":"57938万元","survey":" 圣湘生物科技股份有限公司的主营业务是提供诊断试剂、仪器、第三方医学检验服务为一体的体外诊断整体解决方案。公司的主要产品是诊断试剂、诊断仪器、检测服务。公司连续两年荣登全球医疗器械企业TOP100榜单,入选“国家企业技术中心”“湖南省制造业创新中心”,在iDASH国际隐私计算竞赛中斩获全球第一名,长沙高新区仓储物流中心获批国家级行业认证“五星级仓库”。董事长戴立忠先生当选中国思南峰会2024-2025轮值主席、第三届中国慈善联合会副会长、第四届湖南省慈善总会副会长等职务,并先后作为第十三届、十四届全国人大代表在生命健康领域建言献策,“圣湘声音”与国家战略高度同频共振。","listedPrice":50.48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣湘生物,688289,圣湘生物股票,圣湘生物股票老虎,圣湘生物股票老虎国际,圣湘生物行情,圣湘生物股票行情,圣湘生物股价,圣湘生物股市,圣湘生物股票价格,圣湘生物股票交易,圣湘生物股票购买,圣湘生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}